AUTHOR=Wang Fang , Wang Jin , Zhang Hongjiang , Fu Baobao , Zhang Yanshun , Jia Qianqian , Wang Yong 

TITLE=Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1374674

DOI=10.3389/fonc.2024.1374674

ISSN=2234-943X

ABSTRACT=<sec><title>Backgrounds</title><p>The value of circulating microRNA (miR)-155 for breast cancer (BC) diagnosis may differ in different studies. Therefore, we conducted this systematic review and meta-analysis to evaluate the potential application of circulating miR-155 in the diagnosis of BC.</p></sec><sec><title>Methods</title><p>Articles published before December 2023 and in English were searched in these databases: PubMed, Web of Science, Medline, EMBASE and Google Scholar. A summary of sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR) were calculated from the true positive (TP), true negative (TN), false positive (FP) and false negative (FN) of each study. Additionally, the summary receive-operating characteristics (SROC) curve was constructed to summarize the TP and FP rates.</p></sec><sec><title>Results</title><p>The pooled parameters calculated were as follows: sensitivity, 0.93 (95% CI: 0.83-0.97); specificity, 0.85 (95% CI: 0.74-0.92); PLR, 6.4 (95% CI: 3.4-11.9); NLR, 0.09 (95% CI: 0.04-0.20); and DOR, 74 (95% CI: 22-247). The analysis showed a significant heterogeneity (sensitivity, I<sup>2</sup> = 95.19%, <italic>p</italic> &lt; 0.001; specificity, I<sup>2</sup> = 95.29%, <italic>p</italic> &lt; 0.001; DOR, I<sup>2</sup> = 92.9%, <italic>p</italic> &lt; 0.001). The SROC curve was with an area under curve (AUC) of 0.95 (95% CI: 0.93-0.97).</p></sec><sec><title>Conclusion</title><p>Circulating miR-155 has a potential in the diagnosis of BC.</p></sec>